ABSTRACT

Despite a short history since its first isolation, Akkermansia muciniphila has been extensively studied in relation to its effects on human metabolism. A recent human intervention study also demonstrated that the bacterium is safe to use for therapeutic purposes. The best-known effects of A. muciniphila in human health and disease relate to its ability to strengthen gut integrity, modulate insulin resistance, and protect the host from metabolic inflammation. A further molecular mechanism, induction of GLP-1 secretion through ICAM-2 receptor, was recently discovered with the identification of a new bacterial protein produced by A. muciniphila. However, other studies have suggested a detrimental role for A. muciniphila in specific host immune settings. Here, we evaluate the molecular, mechanistic effects of A. muciniphila in host health and suggest some of the missing links to be connected before the organism should be considered as a next-generation biotherapeutic agent.

摘要

尽管自首次分离以来的历史很短，但Akkermansia muciniphila已就其对人体新陈代谢的影响进行了广泛研究。最近的一项人为干预研究还表明，该细菌可安全用于治疗目的。A. muciniphila在人类健康和疾病中最著名的作用与其增强肠道完整性、调节胰岛素抵抗和保护宿主免受代谢性炎症的能力有关。最近发现了一种进一步的分子机制，即通过 ICAM-2 受体诱导 GLP-1 分泌，并鉴定了一种由A. muciniphila产生的新细菌蛋白。然而，其他研究表明A. muciniphila的有害作用在特定的宿主免疫环境中。在这里，我们评估了A. muciniphila对宿主健康的分子机制影响，并建议在该生物体被视为下一代生物治疗剂之前将一些缺失的环节联系起来。